GrowingStockReport.com

NASDAQ Decliners Watch List: Zogenix, Inc. (NASDAQ:ZGNX) and Amarin Corporation plc (NASDAQ:AMRN) Added to Equity Profile Report's NASDAQ Decliners Watch List.

 

New York, NY -- (ReleaseWire) -- 04/06/2013 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding Zogenix, Inc. (NASDAQ:ZGNX) and Amarin Corporation plc (NASDAQ:AMRN).

Zogenix, Inc. (NASDAQ:ZGNX) a pharmaceutical company that engages in the development and commercialization of products for the treatment of central nervous system disorders and pain closed down in its previous session (-12.57%) on 1,379,562 shares traded. Zogenix, Inc. (NASDAQ:ZGNX) is currently down (-54.24%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about Zogenix, Inc. (NASDAQ:ZGNX)

Amarin Corporation plc (NASDAQ:AMRN) a biopharmaceutical company that focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases closed down in its previous session (-4.39%) on 3,493,822 shares traded. Amarin Corporation plc (NASDAQ:AMRN) is currently down (-55.2%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about Amarin Corporation plc (NASDAQ:AMRN)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com